| Original Article |
View full article
January 30, 2017
|Vol. 4, Issue 1|
Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: a Multicenter Japanese Retrospective Study
Masako Sato, Masato Takahashi, Kenichi Watanabe, Nobumoto Tomioka, Mitsugu Yamamoto, Yoshiaki Narita, Hiroaki Kato, Masaru Abe, Yukiko Tabata, Masaya Kawada, Motoshi Tamura, Mitsuchika Hosoda, Motoi Baba, Kazuhiro Ogasawara, Tomohiro Oshino, Hiromitsu Akabane, Yasuhiro Suzuki, Masatoshi Kadoya, Kazuhiro Iwai, Yumi Okawa, Kenjiro Misu, Kazuomi Ichinokawa and Hiroko Yamashita
Corresponding author: Hiroko Yamashita, Department of Breast Surgery, Hokkaido University Hospital, Kita 14, Nishi 5, Kita-ku, Sapporo, 060-8648, Japan
Trastuzumab emtansine (T-DM1) is currently approved for the treatment of patients with HER2-positive metastatic breast cancer after failure of prior anti-HER2 therapies. However, the efficacy of T-DM1 in patients who received pertuzumab, and in those patients with brain metastases, is currently unclear.
Citation: Sato M, Takahashi M, Watanabe K, Tomioka N, Yamamoto M, et al. (2017) Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: a Multicenter Japanese Retrospective Study. Int J Cancer Clin Res 4:076.